Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2004 1
2005 1
2010 1
2013 1
2015 1
2016 1
2018 2
2019 2
2020 1
2021 1
2022 3
2023 2
2024 3
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S; Kids-DOTT Trial Investigators and the ATLAS Group. Goldenberg NA, et al. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. JAMA. 2022. PMID: 35015038 Free PMC article. Clinical Trial.
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years.
Goldenberg NA, Schulman S, Kittelson JM, Abshire TC, Casella JF, Dale R, Halperin JL, Hanson J, Kessler CM, Manco-Johnson MJ, McDevitt L, Sidonio RF, Spyropoulos AC, Steg PG, Bonaca MP; Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) Trial Investigators and the Antithrombotic Trials Leadership and Steering (ATLAS) Group. Goldenberg NA, et al. J Thromb Haemost. 2025 Feb;23(2):651-656. doi: 10.1016/j.jtha.2024.09.038. Epub 2024 Oct 24. J Thromb Haemost. 2025. PMID: 39461724 Clinical Trial.
How I treat type 1 plasminogen deficiency.
Shapiro AD, Nakar C. Shapiro AD, et al. Among authors: nakar c. Blood. 2025 Jun 19;145(25):2954-2965. doi: 10.1182/blood.2024026973. Blood. 2025. PMID: 40089996
An international registry of patients with plasminogen deficiency (HISTORY).
Shapiro AD, Menegatti M, Palla R, Boscarino M, Roberson C, Lanzi P, Bowen J, Nakar C, Janson IA, Peyvandi F. Shapiro AD, et al. Among authors: nakar c. Haematologica. 2020 Mar;105(3):554-561. doi: 10.3324/haematol.2019.241158. Epub 2020 Jan 30. Haematologica. 2020. PMID: 32001536 Free PMC article. Review.
Treatment of Ligneous Conjunctivitis with Plasminogen Eyedrops.
Caputo R, Shapiro AD, Sartori MT, Leonardi A, Jeng BH, Nakar C, Di Pasquale I, Price FW Jr, Thukral N, Suffredini AL, Pino L, Crea R, Mathew P, Calcinai M. Caputo R, et al. Among authors: nakar c. Ophthalmology. 2022 Aug;129(8):955-957. doi: 10.1016/j.ophtha.2022.03.019. Epub 2022 Mar 26. Ophthalmology. 2022. PMID: 35346720 No abstract available.
25 results